Evidence map›Paper›PMID 26452603›Full record

ArticleGlycoconjugate journal2015

Preparation of legionaminic acid analogs of sialo-glycoconjugates by means of mammalian sialyltransferases.

David C Watson, Warren W Wakarchuk, Christian Gervais, Yves Durocher, Anna Robotham, Steve M Fernandes, Ronald L Schnaar, N Martin Young, Michel Gilbert

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

David C WatsonHuman Health Therapeutics, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Warren W WakarchukDepartment of Chemistry and Biology, Ryerson University, 350 Victoria St., Toronto, ON, M5B 2K3, Canada.
Christian GervaisHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada.
Yves DurocherHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC, H4P 2R2, Canada.
Anna RobothamHuman Health Therapeutics, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Steve M FernandesDepartment of Pharmacology, Johns Hopkins School of Medicine, 725 N. Wolfe Street, Baltimore, MD, 21205, USA.
Ronald L SchnaarDepartment of Pharmacology, Johns Hopkins School of Medicine, 725 N. Wolfe Street, Baltimore, MD, 21205, USA.
N Martin YoungHuman Health Therapeutics, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Michel GilbertHuman Health Therapeutics, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada. michel.gilbert@nrc-cnrc.gc.ca.
National Research Council Canada · CAJohns Hopkins University · USToronto Metropolitan University · CA

Funding

Treating lung inflammation by targeting SiglecsP01HL107151 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SCHNAAR, RONALD L · 2011 to 2017
$15.4M
NHLBI NIH HHS P01 HL107151
6 · The paper itself

Abstract

Legionaminic acids are analogs of sialic acid that occur in several bacteria. The most commonly occurring form is Leg5Ac7Ac, which differs from Neu5Ac only at the C7 (acetamido) and C9 (deoxy) positions. While these differences greatly reduce the susceptibility of Leg compounds to sialidases, several sialyltransferases have been identified that can use CMP-Leg5Ac7Ac as a donor (Watson et al. 2011). We report the successful modification with Leg5Ac7Ac of a glycolipid, GM1a, and two glycoproteins, interferon-α2b and α1-antitrypsin, by means of two mammalian sialyltransferases, namely porcine ST3Gal1 and human ST6Gal1. The Leg5Ac7Ac form of GD1a was not recognized by the myelin-associated glycoprotein (MAG, Siglec-4), confirming the importance of the glycerol moiety in the interaction of sialo-glycans with Siglecs.

Indexed as

alpha 1-AntitrypsinAnimalsG(M1) GangliosideHumansInterferon-alphaMyelin-Associated GlycoproteinProtein BindingSialic AcidsSialyltransferasesSwine5,7-diacetamido-8-O-acetyl-3,5,7,9-tetradeoxy-glycero-talo-nonulosonic acidalpha 1-AntitrypsinG(M1) GangliosideInterferon-alphaMyelin-Associated GlycoproteinSialic AcidsSialyltransferasesGD1aHuman ST6Gal1 sialyltransferaseInterferon-α2bPorcine ST3Gal1 sialyltransferaseα1-antitrypsin

Identifiers

PMID26452603
OpenAlexW1829512616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.